A Phase I/II Clinical Study of Foritinib Succinate in Non-small Cell Lung Cancer (NSCLC) Patients

Conditions:   Advanced Cancer;   Advanced Solid Tumor;   Lung Cancer, Nonsmall Cell Intervention:   Drug: SAF-189 Sponsor:   Shanghai Fosun Pharmaceutical Development Co, Ltd. Recruiting

Source: ClinicalTrials.gov - January 23, 2020 Category: Research Source Type: clinical trials